



**Vaccines and Global Health: The Week in Review**  
**29 February 2020 :: Number 543**  
**Center for Vaccine Ethics & Policy (CVEP)**

*This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.*

*Vaccines and Global Health: The Week in Review is also **posted in pdf form** and as a set of blog posts at <https://centerforvaccineethicsandpolicy.net>. This blog allows full-text searching of over 8,000 entries.*

*Comments and suggestions should be directed to*

*David R. Curry, MS*

*Editor and*

*Executive Director*

*Center for Vaccine Ethics & Policy*

*[david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)*

***Request an email version:*** *Vaccines and Global Health: The Week in Review is published as a single email summary, scheduled for release each Saturday evening at midnight (EST/U.S.). If you would like to receive the email version, please send your request to [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org).*

***Support this knowledge-sharing service:*** *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

**Contents** *[click on link below to move to associated content]*

A. [Milestones :: Perspectives :: Featured Journal Content](#)

B. [Emergencies](#)

C. [WHO; CDC \[U.S., Africa, China\]](#)

D. [Announcements](#)

E. [Journal Watch](#)

F. [Media Watch](#)



## ***Milestones :: Perspectives :: Research***



### **Global institutions must act urgently and decisively to tackle COVID-19**

*Opinion* | 27 February 2020

Jeremy Farrar, Director, Wellcome Trust

*The COVID-19 outbreak is not just a public health crisis, it's rapidly becoming a global crisis – of health, economics and politics.*

A queue of Italian shoppers outside a supermarket with empty trolleys. It's not an image we automatically associate with a global public health crisis. But when this picture, from the quarantined Lombardy town of Casalpusterlengo, led news reports earlier this week, it captured something infectious disease researchers, like me, have been struggling to express clearly. It is that epidemics like COVID-19 are so much more than just a public health crisis. Like the worst financial crashes, they are global events, which can impact every sector of society all at once.

For the people of Lombardy and Veneto – and those of Daegu in South Korea, and Wuhan and many more towns and cities in China – fear of falling ill is just the start. With quarantine, or even containment tactics that do much less to infringe civil liberties, the social disruption is everywhere. The supermarket with empty shelves. The trains that don't run. The shuttered workplace. The children sent home from school. The features of normal life we take for granted turned upside down.

These social impacts feed economic ones and have sent most of the world's major stock exchanges sharply downwards in the past few days. Cruise ships, prisons, hotels and villages in one part of the world could just as easily be care homes, schools, work places or refugee camps in another. Even with scientists' best estimates, it is near-impossible to predict whether this virus will stay with us long-term, or, like the SARS outbreak in 2003, will burn out. But what can we do to curb this wider societal contagion?

In the past month, governments around the world have stepped up public health responses, from airport screenings and quarantining potential cases on the return from affected areas, to finding extra capacity for national health services. These actions have been crucial to reducing and delaying the spread of this virus – because, as yet, we have no vaccine or proven treatment. Communities, particularly in China, have paid a heavy price, but have bought the rest of the world critical time.

What more, then? I believe our greatest weapon against uncertainty and panic is trust, which in much of the world is at a historic low. To regain it, our global powers, including the World Bank, International Monetary Fund (IMF), and leaders of the G7 and G20, must make decisions that demonstrate they see this as a global crisis, and continue the current containment approach while also preparing for the worst. Three key pieces of insight should help kickstart action.

First, agreement that the chances of this becoming something that we can't contain are uncomfortably high and acting as if this is a certainty is now our best bet. Second, decisions

must keep pace with this epidemic, which means coordinated action should be adapted as needed on an almost daily basis. Third, and as the residents of northern Italy and South Korea already know, recognising that the possible impact of coronavirus is far beyond a health emergency – it's a global crisis with the potential to reach the scale of the global financial crisis of 2008.

Then, global financial institutions such as the IMF and World Bank were admirably swift to act. They did what the world needed – and while negative consequences couldn't be avoided, the immediate impact was to some extent mitigated. These same institutions can no longer stand by in the face of a crisis that is no less threatening. They are designed to be the world's insurance policy and they must release the significant funds they hold without hesitation.

Anything less than an urgent initial commitment of \$10 billion from the World Bank leaves us at risk of much greater costs later and long-term catastrophe. The sums are considerable. The decision to release funds should not be taken lightly, but the stakes could not be higher. Economists have previously warned that even a moderately severe pandemic could knock 4-5% off global output.

The investment should be used to bolster the public health response in the most vulnerable countries, coordinated through the World Health Organization, and to develop diagnostics, treatments and vaccines. If COVID-19 burns out, then the hours and money spent on our response will not have been wasted but will represent a crucial investment in global health.

Likewise, the IMF needs to ensure it allocates appropriate capital to support central banks across the world. The economic impact of an epidemic can be devastating, particularly on low- and middle-income countries and small businesses. When SARS spread through Asia in 2003, it cost the world economy \$60 billion in less than a year. The Ebola epidemic of 2014-15 more than halved Liberia's GDP growth that year. Maintaining access to credit while we weather the storm is vital.

Those with wealth and power must ensure that no country is left behind, particularly those with vulnerable health care systems and fragile economies. This is not just a public health crisis, it's rapidly becoming a global crisis – of health, economics and politics. The best of the world's multilateral financial and political institutions need to ask themselves what they can do to help avert it, and how they can build trust in themselves in the process. The world needs these institutions to act urgently and decisively.

#### *Related content*

Wellcome has launched a [COVID-19 funding call](#) to support researchers who want to investigate new approaches for preventing and controlling the epidemic, with a focus on low- and middle-income countries.

.....  
.....

## **EMERGENCIES**

### ***Editor's Note:***

While we have concentrated the most current key reports just below, COVID-19 announcements, analysis and commentary will be found throughout this issue, in all sections.

Beyond the considerable continuing coverage in the global general media:

**Daily WHO situation reports** here: <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports>

**WHO Coronavirus disease (COVID-2019) daily press briefings** here: <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/media-resources/press-briefings>

## **Coronavirus [COVID-19]**

*Public Health Emergency of International Concern (PHEIC)*

[Situation report - 39](#) [WHO]

Novel Coronavirus (COVID-19)

28 February 2020

*[Excerpts]*

### **SITUATION IN NUMBERS**

Globally :: 83,652 laboratory-confirmed [1358 new]

*[Week ago: 77,794 laboratory-confirmed [599 new]]*

China :: 78,961 laboratory-confirmed [331 new]

:: 2,791 deaths [109 new]

Outside of China

:: 4,691 laboratory-confirmed [1027 new]

:: 52 countries *[28 countries last week]*

:: 67 deaths [10 new]

### **WHO RISK ASSESSMENT**

China - Very High

**Regional Level – Very High**

**Global Level – Very High**

### **HIGHLIGHTS**

:: Five new Member States (Belarus, Lithuania, Netherlands, New Zealand, and Nigeria) reported cases of COVID-19 in the past 24 hours.

:: WHO has increased the assessment of the risk of spread and risk of impact of COVID-19 to very high at the global level. More information can be found here.

:: The WHO-China Joint Mission, which was conducted from 16 through 24 February, has published its findings. The full report can be found here.

:: WHO has updated the guidance on Global Surveillance for human infection with coronavirus disease (COVID-19). This document includes revised surveillance case definitions for COVID-19.

:: As of 27 February, there are 36 117 (26 403 in Hubei and 15 826 in Wuhan) cases who have recovered from COVID-19 in China.

:: Under the International Health Regulations (2005), States Parties implementing additional health measures that significantly interfere with international traffics shall notify WHO of the public health rationale of those measures within 48 hours of their implementation. As of 27 February, 41 States Parties are officially reporting additional health measures.

.....

[Here is the report of the WHO-China Joint Mission on Coronavirus Disease 2019 \(COVID-19\), published as received from the mission, unabridged by WHO](#)

16-24 February 2020 :: 40 pages

*Excerpt*

**IV. Major Recommendations**

***For China***

1. Maintain an appropriate level of emergency management protocols, depending on the assessed risk in each area and recognizing the real risk of new cases and clusters of COVID-19 as economic activity resumes, movement restrictions are lifted, and schools reopen;
2. Carefully monitor the phased lifting of the current restrictions on movement and public gatherings, beginning with the return of workers and migrant labor, followed by the eventual reopening of schools and lifting other measures;
3. Further strengthen the readiness of emergency management mechanisms, public health institutions (e.g. CDCs), medical facilities, and community engagement mechanisms to ensure sustained capacity to immediately launch containment activities in response to any resurgence in cases;
4. Prioritize research that rapidly informs response and risk management decisions, particularly household and health care facility studies, age-stratified seroepidemiologic surveys and rigorous investigation of the animal-human interface; establish a centralized research program to fast-track the most promising rapid diagnostics and serologic assays, the testing of potential antivirals and vaccine candidates, and Chinese engagement in selected multi-country trials; and
5. As the country with the greatest knowledge on COVID-19, further enhance the systematic and real-time sharing of epidemiologic data, clinical results and experience to inform the global response.

**For countries with imported cases and/or outbreaks of COVID-19**

1. Immediately activate the highest level of national Response Management protocols to ensure the all-of-government and all-of-society approach needed to contain COVID-19 with non-pharmaceutical public health measures;
2. Prioritize active, exhaustive case finding and immediate testing and isolation, painstaking contact tracing and rigorous quarantine of close contacts;
3. Fully educate the general public on the seriousness of COVID-19 and their role in preventing its spread;
4. Immediately expand surveillance to detect COVID-19 transmission chains, by testing all patients with atypical pneumonias, conducting screening in some patients with upper respiratory illnesses and/or recent COVID-19 exposure, and adding testing for the COVID-19 virus to existing surveillance systems (e.g. systems for influenza-like-illness and SARI); and
5. Conduct multi-sector scenario planning and simulations for the deployment of even more stringent measures to interrupt transmission chains as needed (e.g. the suspension of large-scale gatherings and the closure of schools and

workplaces).

### **For uninfected countries**

1. Prepare to immediately activate the highest level of emergency response mechanisms to trigger the all-of-government and all-of society approach that is essential for early containment of a COVID-19 outbreak;
2. Rapidly test national preparedness plans in light of new knowledge on the effectiveness of non-pharmaceutical measures against COVID-19; incorporate rapid detection, largescale case isolation and respiratory support capacities, and rigorous contact tracing and management in national COVID-19 readiness and response plans and capacities;
3. Immediately enhance surveillance for COVID-19 as rapid detection is crucial to containing spread; consider testing all patients with atypical pneumonia for the COVID-19 virus, and adding testing for the virus to existing influenza surveillance systems;
4. Begin now to enforce rigorous application of infection prevention and control measures in all healthcare facilities, especially in emergency departments and outpatient clinics, as this is where COVID-19 will enter the health system; and
5. Rapidly assess the general population's understanding of COVID-19, adjust national health promotion materials and activities accordingly, and engage clinical champions to communicate with the media.

### **For the public**

1. Recognize that COVID-19 is a new and concerning disease, but that outbreaks can be managed with the right response and that the vast majority of infected people will recover;
2. Begin now to adopt and rigorously practice the most important preventive measures for COVID-19 by frequent hand washing and always covering your mouth and nose when sneezing or coughing;
3. Continually update yourself on COVID-19 and its signs and symptoms (i.e. fever and dry cough), because the strategies and response activities will constantly improve as new information on this disease is accumulating every day; and
4. Be prepared to actively support a response to COVID-19 in a variety of ways, including the adoption of more stringent 'social distancing' practices and helping the high-risk elderly population.

23

### **For the international community**

1. Recognize that true solidarity and collaboration is essential between nations to tackle the common threat that COVID-19 represents and operationalize this principle;
2. Rapidly share information as required under the International Health Regulations (IHR) including detailed information about imported cases to facilitate contact tracing and inform containment measures that span countries;
3. Recognize the rapidly changing risk profile of COVID-19 affected countries and

continually monitor outbreak trends and control capacities to reassess any 'additional health measures' that significantly interfere with international travel and trade.

### [WHO Director-General's opening remarks at media briefing on COVID-19 \(28 February 2020\)](#)

27 February 2020 *Statement*

#### [A Joint Statement on Tourism and COVID-19 - UNWTO and WHO Call for Responsibility and Coordination](#)

As the current outbreak of the Coronavirus Disease (COVID-19) continues to develop, the World Health Organization (WHO) and the World Tourism Organization (UNWTO) are committed to working together in guiding the travel and tourism sectors' response to COVID-19.

On 30 January 2020, the Director-General of the World Health Organization (WHO) declared the outbreak of COVID-19 to be a Public Health Emergency of International Concern and issued a set of Temporary Recommendations. WHO did not recommend any travel or trade restriction based on the current information available. WHO is working closely with global experts, governments and partners to rapidly expand scientific knowledge on this new virus, to track the spread and virulence of the virus, and to provide advice to countries and the global community on measures to protect health and prevent the spread of this outbreak.

#### *Cooperation is key*

The tourism sector is fully committed to putting people and their well-being first. International cooperation is vital for ensuring the sector can effectively contribute to the containment of COVID-19. UNWTO and WHO are working in close consultation and with other partners to assist States in ensuring that health measures be implemented in ways that minimize unnecessary interference with international traffic and trade.

**Tourism's response needs to be measured and consistent, proportionate to the public health threat and based on local risk assessment, involving every part of the tourism value chain – public bodies, private companies and tourists, in line with WHO's overall guidance and recommendations.**

UNWTO and WHO stand ready to work closely with all those communities and countries affected by the current health emergency, to build for a better and more resilient future. Travel restrictions going beyond these may cause unnecessary interference with international traffic, including negative repercussions on the tourism sector.

At this challenging time, UNWTO and WHO join the international community in standing in solidarity with affected countries.

.....

### [Moderna Ships mRNA Vaccine Against Novel Coronavirus \(mRNA-1273\) for Phase 1 Study](#)

February 24, 2020

## **Clover and GSK Announce Research Collaboration to Evaluate Coronavirus (COVID-19) Vaccine Candidate with Pandemic Adjuvant System**

February 24, 2020

.....  
.....

### **Emergencies**

#### **Ebola – DRC+**

*Public Health Emergency of International Concern (PHEIC)*

#### **Ebola Outbreak in DRC 81: 23 February 2020**

*[Excerpts]*

##### ***Situation Update***

This week, the incidence of new confirmed Ebola virus disease (EVD) cases remained low (Figure 1). From 17 to 23 February 2020, one new confirmed case was reported in the Democratic Republic of the Congo. The case was reported in Beni Health Zone, North Kivu Province on 17 February 2020. The person is a contact of a confirmed case, was under surveillance at the time of illness onset, and is now receiving care at an Ebola Treatment Centre.

In the past 21 days (3 to 23 February 2020), the outbreak has been confined to a relatively small geographic area. During this period, five new confirmed cases were reported from two health areas in North Kivu Province; both areas are within Beni Health Zone (Figure 2, Table 1). It has been more than 21 days since new cases were confirmed from Mabalako Health Zone, and over 42 days since new cases were detected in Musienene Health Zone.

While we are cautiously optimistic about the overall trend and reduced geographic spread of the outbreak, the risk of resurgence within the Democratic Republic of the Congo and neighbouring countries remains high, and the continued containment of the outbreak is contingent on maintaining access and security in affected communities...

##### ***...Conclusion***

For the third consecutive week, new confirmed cases have only been reported from Beni Health Zone. While there is room for cautious optimism regarding the low number of new confirmed cases reported recently, continued access and heightened vigilance is required to mitigate risks of potential re-emergence of the outbreak.

.....  
.....

### **Emergencies**

#### **POLIO**

*Public Health Emergency of International Concern (PHEIC)*

<http://polioeradication.org/polio-today/polio-now/this-week/>

## **Polio this week as of 26 February 2020**

:: Do you wish to become a member of the Polio Transition Independent Monitoring Board? If so, you are invited to send in your application by 11 March 2020. Details of role requirements can be found [here](#).

:: To know more about the state of poliovirus surveillance and the opportunities explored to enhance surveillance in priority areas, take a look at the newly released [2019 Global Polio Surveillance Status Report](#).

### ***Summary of new viruses this week (AFP cases and ES positives):***

:: ***Afghanistan:*** one WPV1 positive environmental sample

:: ***Pakistan:*** two WPV1 cases and 14 WPV1 positive environmental samples

:: ***Central African Republic:*** one cVDPV2 positive environmental sample

:: ***Benin:*** one cVDPV2 case

:: ***Ghana:*** six cVDPV2 cases and two cVDPV2 positive environmental samples

:: ***Togo:*** two cVDPV2 cases

.....  
.....

## **WHO Grade 3 Emergencies** [to 29 Feb 2020]

### **Democratic Republic of the Congo**

:: [Ebola Outbreak in DRC 81: 23 February 2020](#)

[See Emergencies above for detail]

### **Nigeria**

:: [WHO reaffirms commitment to support Nigeria in response to COVID19](#)

28 February 2020

[Mozambique floods](#) - *No new digest announcements identified*

[Somalia](#) - *No new digest announcements identified*

[South Sudan](#) - *No new digest announcements identified*

[Syrian Arab Republic](#) - *No new digest announcements identified*

[Yemen](#) - *No new digest announcements identified*

.....

## **WHO Grade 2 Emergencies** [to 29 Feb 2020]

### **Measles in Europe**

:: [Supporting Serbia to strengthen health systems and improve health](#) 28-02-2020

### **Iraq**

:: [WHO delivers ambulances to strengthen referral pathways in Kurdistan region of Iraq](#)

Erbil, 17 February 2020 – The World Health Organization (WHO) today handed over a new batch of fully equipped ambulances to the Ministry of Health in Kurdistan Region of Iraq to support the needs of internally displaced persons (IDP) and the host community.

[Afghanistan](#) - *No new digest announcements identified*

Angola - *No new digest announcements identified*  
Burkina Faso [in French] - *No new digest announcements identified*  
Burundi - *No new digest announcements identified*  
Cameroon - *No new digest announcements identified*  
Central African Republic - *No new digest announcements identified*  
Ethiopia - *No new digest announcements identified*  
HIV in Pakistan - *No new digest announcements identified*  
Iran floods 2019 - *No new digest announcements identified*  
Libya - *No new digest announcements identified*  
Malawi floods - *No new digest announcements identified*  
MERS-CoV - *No new digest announcements identified*  
Myanmar - *No new digest announcements identified*  
Niger - *No new digest announcements identified*  
occupied Palestinian territory - *No new digest announcements identified*  
Sudan - *No new digest announcements identified*  
Ukraine - *No new digest announcements identified*  
Zimbabwe - *No new digest announcements identified*

.....

#### **WHO Grade 1 Emergencies** [to 29 Feb 2020]

Chad - *No new digest announcements identified*  
Djibouti - *No new digest announcements identified*  
Kenya - *No new digest announcements identified*  
Mali - *No new digest announcements identified*  
Namibia - viral hepatitis - *No new digest announcements identified*  
Tanzania - *No new digest announcements identified*

.....  
.....

#### **UN OCHA – L3 Emergencies**

*The UN and its humanitarian partners are currently responding to three 'L3' emergencies. This is the global humanitarian system's classification for the response to the most severe, large-scale humanitarian crises.*

#### **Syrian Arab Republic**

**:: Recent Developments in Northwest Syria - Situation Report No. 9 - As of 26 February 2020**  
**HIGHLIGHTS**

More than 948,000 people have been displaced in northwest Syria since 1 December 2019. Some 569,000 of them are children and over 195,000 of them are women, together comprising 81 percent of the newly displaced population.

The current crisis is the worst that northwest Syria has experienced since the beginning of the conflict. More people have been displaced into a smaller area in a shorter period of time than ever before, with nowhere else to flee. Lives are increasingly at risk as increasing numbers of people are concentrated in smaller areas. Many are moving to unsafe areas as they have no other options. Their vulnerability and desperation is increasing, with reports of exploitation of women and girls, the separation of children from their families, and increasing rates of malnutrition.

The humanitarian community has revised its readiness and response plan to reflect the needs of the newly displaced people, host communities and people who had previously been displaced. Increased funding, reprogramming flexibility and other support is needed to enable humanitarian partners to suitably scale up the emergency response. Most importantly, an immediate cessation of violence is critical to save lives and alleviate suffering of hundreds of thousands of people.

Yemen - *No new digest announcements identified*

.....

### **UN OCHA – Corporate Emergencies**

When the USG/ERC declares a Corporate Emergency Response, all OCHA offices, branches and sections provide their full support to response activities both at HQ and in the field.

CYCLONE IDAI and Kenneth - *No new digest announcements identified*

EBOLA OUTBREAK IN THE DRC - *No new digest announcements identified*

.....

.....

### **WHO & Regional Offices** [to 29 Feb 2020]

27 February 2020 *Statement*

#### **A Joint Statement on Tourism and COVID-19 - UNWTO and WHO Call for Responsibility and Coordination**

*[See COVID-19 above for detail]*

24 February 2020 *News release*

#### **France pledges US\$100 million (€90 million) for WHO Academy**

.....

### **Weekly Epidemiological Record, 21 February 2020, vol. 95, 08 (pp. 69–76)**

:: Progress towards measles elimination – China, January 2013–June 2019

:: COVID-19 update

.....

### **WHO Regional Offices**

*Selected Press Releases, Announcements*

#### **WHO African Region AFRO**

:: Nigeria targets nearly 12 million in Yellow fever vaccination across two high risk S...

28 February 2020

#### **WHO Region of the Americas PAHO**

:: Face masks during outbreaks: Who, when, where and how to use them (02/28/2020)

:: PAHO Director calls on countries of the Americas to intensify COVID-19 preparedness and response activities (02/26/2020)

#### **WHO South-East Asia Region SEARO**

:: 27 January 2020 *News release*

Readiness is the key to detect, combat spread of the new coronavirus

:: 26 December 2019 *News release*

15 years of Indian Ocean tsunami - WHO South-East Asia Region continues to prioritize preparedness to respond to public health emergencies

### **WHO European Region EURO**

:: Supporting Serbia to strengthen health systems and improve health 28-02-2020

:: Smartphone app aids midwives in Kyrgyzstan 28-02-2020

:: Statement for the joint press conference on COVID-19 26-02-2020

:: Joint WHO and ECDC mission in Italy to support COVID-19 control and prevention efforts 24-02-2020

### **WHO Eastern Mediterranean Region EMRO**

*No new digest content identified.*

### **WHO Western Pacific Region**

*No new digest content identified.*

.....  
.....

**CDC/ACIP** [to 29 Feb 2020]

<http://www.cdc.gov/media/index.html>

<https://www.cdc.gov/vaccines/acip/index.html>

*Latest News Releases*

**CDC Announces Additional COVID-19 Presumptive Positive Cases** Friday, February 28, 2020

**Transcript for the CDC Telebriefing Update on COVID-19** Friday, February 28, 2020

**CDC Confirms Possible Instance of Community Spread of COVID-19 in U.S.**

Wednesday, February 26, 2020

**Transcript for the CDC Telebriefing Update on COVID-19** Wednesday, February 26, 2020

**MMWR News Synopsis Friday, February 28, 2020**

**Update: Public Health Response to the Coronavirus Disease 2019 Outbreak — United States, February 24, 2020**

.....

**Africa CDC** [to 29 Feb 2020]

<http://www.africacdc.org/>

*News*

**African Union Mobilizes Continent-Wide Response to COVID-19 Outbreak**

ADDIS ABABA, ETHIOPIA, 24 FEBRUARY 2020. The Chairperson, African Union Commission, H.E. Mr Moussa Faki Mahamat, said that the Commission will strengthen partnerships and

coordination across Africa to to respond to the 2019 novel coronavirus disease (COVID-19) outbreak...

.....

### **China CDC**

<http://www.chinacdc.cn/en/>

*No new digest content identified.*

### **National Health Commission of the People's Republic of China**

<http://en.nhc.gov.cn/>

*News*

#### **[Feb 29: Daily briefing on novel coronavirus cases in China](#)**

On Feb 28, 31 provincial-level regions on the Chinese mainland as well as the Xinjiang Production and Construction Corps reported 427 new cases of confirmed infections, 248 new cases of suspected infections, and 47 deaths.

#### **[Li urges more R&D in outbreak fight](#)**

2020-02-29

*Premier calls for developing enhanced test kits, pharmaceuticals, vaccines*

Premier Li Keqiang urged greater breakthroughs in the research and development of more efficient test kits, pharmaceuticals and vaccines to help the country better battle the novel coronavirus epidemic.

Li's remark on Friday came as he visited a national emergency response platform in Beijing coping with the COVID-19 outbreak...

#### **[Epidemic easing at its epicenter](#)**

2020-02-29

#### **[Health official calls for caution as work resumes](#)**

2020-02-29

.....

.....

### **Announcements**

**Paul G. Allen Frontiers Group** [to 29 Feb 2020]

<https://alleninstitute.org/what-we-do/frontiers-group/news-press/>

*News*

*No new digest content identified.*

**BMGF - Gates Foundation** [to 29 Feb 2020]

<http://www.gatesfoundation.org/Media-Center/Press-Releases>

FEBRUARY 24, 2020

**[Bill & Melinda Gates Foundation Commits \\$10 Million to Support Global Response on East Africa Locust Invasion](#)**

SEATTLE February 24, 2020 – The Bill & Melinda Gates Foundation announced today that it is contributing \$10 million to the United Nations Food and Agriculture Organization (FAO) to support its work with governments in Ethiopia, Kenya, and Somalia, to combat a locust infestation in East Africa that is posing a significant threat to food production and livelihoods in the region. The foundation is joining several other donors in responding to FAO's urgent appeal to contain the crisis.

**Bill & Melinda Gates Medical Research Institute** [to 29 Feb 2020]

<https://www.gatesmri.org/>

*The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people  
No new digest content identified.*

**CARB-X** [to 29 Feb 2020]

<https://carb-x.org/>

*CARB-X is a non-profit public-private partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.*

02.25.2020 |

**[CARB-X funds Peptilogics to develop a new class of antibiotics to treat serious superbug infections associated with implants](#)**

CARB-X is awarding Peptilogics, headquartered in Pittsburgh, USA, up to US\$2.56 million in non-dilutive funding to develop a new class of peptide antibiotics with broad activity against drug-resistant bacteria. The company could receive up to \$9.61 million more in additional funding if the project achieves certain development milestones, for a potential total of up to \$12.17 million.

**CEPI – Coalition for Epidemic Preparedness Innovations** [to 29 Feb 2020]

<http://cepi.net/>

*News*

*No new digest content identified.*

**Clinton Health Access Initiative, Inc. (CHAI)** [to 29 Feb 2020]

<https://clintonhealthaccess.org/>

*News & Press Releases*

*No new digest content identified.*

**EDCTP** [to 29 Feb 2020]

<http://www.edctp.org/>

*The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against*

*HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials*  
*Latest news*  
*No new digest content identified.*

**Emory Vaccine Center** [to 29 Feb 2020]

<http://www.vaccines.emory.edu/>

*No new digest content identified.*

**European Medicines Agency** [to 29 Feb 2020]

<http://www.ema.europa.eu/ema/>

*News & Press Releases*

**[News: Meeting highlights from the Committee for Medicinal Products for Human Use \(CHMP\) 24-27 February 2020](#)**

CHMP, Last updated: 28/02/2020

**European Vaccine Initiative** [to 29 Feb 2020]

<http://www.euvaccine.eu/news-events>

*No new digest content identified.*

**FDA** [to 29 Feb 2020]

<https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/default.htm>

*Press Announcements*

**[Coronavirus \(COVID-19\) Update: FDA Issues New Policy to Help Expedite Availability of Diagnostics](#)**

Feb 29, 2020, 10:33 ET

...The new policy is for certain laboratories that develop and begin to use validated COVID-19 diagnostics before the FDA has completed review of their [Emergency Use Authorization \(EUA\)](#) requests. The FDA can issue an EUA to permit the use, based on scientific data, of certain medical products that may be effective in diagnosing, treating or preventing a disease or condition when there is a determination, by the Secretary of Health and Human Services (HHS), that there is a public health emergency or a significant potential for a public health emergency that has a significant potential to affect national security or the health and security of U.S. citizens, and a declaration that circumstances exist justifying the medical products' emergency use.

On Feb. 4, 2020, the Secretary of HHS determined that there is a public health emergency and that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of the COVID-19 outbreak. Rapid detection of COVID-19 cases in the U.S. requires wide availability of diagnostic testing to control the emergence of a rapidly spreading, severe illness. The FDA has authorized one EUA for COVID-19 that is in use by the U.S. Centers for Disease Control and Prevention (CDC) and some public health labs across the country.

The guidance issued today describes a policy enabling laboratories to immediately use tests they developed and validated in order to achieve more rapid testing capacity in the U.S...

### **February 27, 2020 - Coronavirus (COVID-19) Supply Chain Update**

...Since January 24, the FDA has been in touch with more than 180 manufacturers of human drugs, not only to remind them of applicable legal requirements for notifying the FDA of any anticipated supply disruptions, but also asking them to evaluate their entire supply chain, including active pharmaceutical ingredients (the main ingredient in the drug and part that produces the intended effects, e.g., acetaminophen) and other components manufactured in China.

Also, as part of our efforts, the FDA has identified about 20 other drugs, which solely source their active pharmaceutical ingredients or finished drug products from China. We have been in contact with those firms to assess whether they face any drug shortage risks due to the outbreak. None of these firms have reported any shortage to date. Also, these drugs are considered non-critical drugs.

We will remain in contact with manufacturers so that we can continue to assist them with any potential issues in the fastest way...

### **February 24, 2020 - Coronavirus Update: FDA steps to ensure quality of foreign products**

**Fondation Merieux** [to 29 Feb 2020]

<http://www.fondation-merieux.org/>

*News, Events*

*Mérieux Foundation co-organized event*

**5th Meeting of the GTFCC Water, Sanitation and Hygiene (WASH) Working Group**

March 3 - 4, 2020 - Dar es Salam (Tanzania)

**Gavi** [to 29 Feb 2020]

<https://www.gavi.org/>

25 February 2020

**DRC: vaccination sessions increase by 50% in vulnerable provinces since 2018**

:: In the nine provinces where half of all the DRC's under-immunised children live, there are now 24,000 routine vaccination sessions per month

:: New technology enabling health workers to monitor key indicators in real time has contributed to the dramatic increase

:: Progress comes at a time when the country is battling outbreaks of Ebola, measles and cholera, among other diseases

**GHIT Fund** [to 29 Feb 2020]

<https://www.ghitfund.org/newsroom/press>

*GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that  
No new digest content identified.*

**Global Fund** [to 29 Feb 2020]

<https://www.theglobalfund.org/en/news/>

*News & Stories*

*Updates*

**[Search for Independent Board Committee Members](#)**

26 February 2020

The Global Fund Board is looking for three independent experts to serve as non-voting members of Global Fund Board standing committees for 2020-2022. Financial audit, forensics investigations and ethics experts are invited to submit applications to serve on the Audit and Finance Committee and the Ethics and Governance Committee. The application deadline is 27 March 2020.

*Updates*

**[Search for Chief Financial Officer and Head of Health Finance](#)**

25 February 2020

**Hilleman Laboratories** [to 29 Feb 2020]

<http://www.hillemanlabs.org/>

*No new digest content identified.*

**Human Vaccines Project** [to 29 Feb 2020]

<http://www.humanvaccinesproject.org/media/press-releases/>

*Press Releases*

*No new digest content identified.*

**IAVI** [to 29 Feb 2020]

<https://www.iavi.org/newsroom>

*No new digest content identified.*

**International Coalition of Medicines Regulatory Authorities [ICMRA]**

<http://www.icmra.info/drupal/en/news>

*Selected Statements, Press Releases, Research*

*No new digest content identified.*

**International Generic and Biosimilar Medicines Association [IGBA]**

<https://www.igbamedicines.org/>

*News*

*No new digest content identified.*

**IFFIm**

<http://www.iffim.org/>

06 Feb 2020

**[IFFIm Vaccine Bond issuance named 2019 "Deal of the Year" by mtn-i](#)**

London, 6 February 2020 -- IFFIm, Skandinaviska Enskilda Banken (SEB) and the Toronto-Dominion Bank have been awarded SRI "Deal of the Year" by news, data and analytics publisher [mtn-i](#) for a July 2019 Vaccine Bond issuance that raised funding to research and develop new vaccines.

The award was given in the SRI: Green/Social category for IFFIm's July 2019 issuance that raised 600 million Norwegian krone (US\$ 65 million) for CEPI, the Coalition for Epidemic Preparedness Innovations. CEPI is a public private initiative that accelerates development of vaccines against emerging infectious diseases and enables equitable access to these vaccines during outbreaks. These bonds provided immediate funding to combat diseases like MERS, Nipah virus and Lassa fever.

The transaction allowed Norway to accelerate its multi-year pledge to CEPI by leveraging IFFIm's access to the capital markets. Norway is a donor to IFFIm, Gavi and CEPI...

**IFRC** [to 29 Feb 2020]

<http://media.ifrc.org/ifrc/news/press-releases/>

*Selected Press Releases, Announcements*

*DPRK*

**[Red Cross granted exemption from UN sanctions to provide humanitarian aid in DPRK](#)**

Pyongyang/Kuala Lumpur/Geneva, 24 February 2020 – The International Federation of Red Cross and Red Crescent Societies (IFRC) has been granted an exemption to United Nations sanctions, imposed on the Democratic People's Republic of Korea by United Nations Security Council Resolution 1718 (2006) and subsequent resolutions, allowing for the provision of life-saving support to protect people from the spread of the new coronavirus, COVID-19.

The potential for an outbreak of COVID-19 in the Democratic People's Republic of Korea poses a threat to millions of people who are already in need of humanitarian assistance.

Xavier Castellanos, IFRC's Asia Pacific Regional Director said: "We know that there is urgent need of personal protective gear and testing kits, items vital to prepare for a possible outbreak. This exemption is a life-saving intervention and an important measure to ensure that sanctions do not bear a negative impact on the people of the Democratic People's Republic of Korea."

**IVAC** [to 29 Feb 2020]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

*Updates*

*No new digest content identified.*

**IVI** [to 29 Feb 2020]

<http://www.ivi.int/>

*Selected IVI News & Announcements*

**[Korea should join efforts in vaccine development to prevent pandemics](#)**

by Jerome H. Kim, Director General of the International Vaccine Institute (IVI)

Feb 26, 2020

Originally published in the JoongAng Ilbo (Korean language) and Korea JoongAng Daily (English language)

**JEE Alliance** [to 29 Feb 2020]

<https://www.jeealliance.org/>

*Selected News and Events*

*No new digest content identified.*

**MSF/Médecins Sans Frontières** [to 29 Feb 2020]

<http://www.msf.org/>

*Latest [Selected Announcements]*

*Syria*

**[MSF to scale up response in Idlib, Syria as tensions reach a new peak](#)**

Statement 28 Feb 2020

*Mediterranean migration*

**[Ocean Viking arbitrarily quarantined by Italian authorities over COVID...](#)**

Project Update 28 Feb 2020

As Italy was hit by the [COVID-19 coronavirus outbreak](#) late last week, the Ocean Viking, [the search and rescue ship](#) operated by Médecins Sans Frontières (MSF) and SOS MEDITERRANEE, was put under quarantine following the disembarkation of 276 people rescued at sea in the prior days.

The Ocean Viking has complied with all measures and has now been anchored off Sicily for five days. It is increasingly clear that quarantine restrictions are being discriminatorily applied only to search and rescue vessels.

“Quarantining the Ocean Viking is equivalent to stopping an ambulance in the middle of an emergency,” said Michael Fark, MSF head of mission for Search and Rescue. “This is a discriminatory action – the only vessels that have been put into quarantine are those conducting rescues.”

In the past 48 hours we have had reports of boats in distress in the central Mediterranean. We are deeply worried about the fate of people travelling in them...

**National Vaccine Program Office - U.S. HHS** [to 29 Feb 2020]

<https://www.hhs.gov/vaccines/about/index.html>

*NVAC 2020 Meetings*

**[June 9-10, 2020 NVAC Meeting](#)**

**[September 23-24, 2020 Meeting \(Virtual\)](#)**

**NIH** [to 29 Feb 2020]

<http://www.nih.gov/news-events/news-releases>

*Selected News Releases*

**[COVID-19 a Reminder of the Challenge of Emerging Infectious Diseases](#)**

February 28, 2020 — The respiratory illness caused by a novel coronavirus poses complex challenges to the global public health, research and medical communities.

**[NIH announces \\$1 million prize competition to target global disease diagnostics](#)**

February 26, 2020 — Bill & Melinda Gates Foundation to offer supplementary support for designs that can be developed into products on a rapid timeframe.

### **[NIH clinical trial of remdesivir to treat COVID-19 begins](#)**

February 25, 2020 — Study enrolling hospitalized adults with COVID-19 in Nebraska.

A randomized, controlled clinical trial to evaluate the safety and efficacy of the investigational antiviral remdesivir in hospitalized adults diagnosed with coronavirus disease 2019 (COVID-19) has begun at the University of Nebraska Medical Center (UNMC) in Omaha. The trial regulatory sponsor is the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. This is the first clinical trial in the United States to evaluate an experimental treatment for COVID-19, the respiratory disease first detected in December 2019 in Wuhan, Hubei Province, China...

**PATH** [to 29 Feb 2020]

<https://www.path.org/media-center/>

*Selected Announcements*

*No new digest content identified.*

**Sabin Vaccine Institute** [to 29 Feb 2020]

<http://www.sabin.org/updates/pressreleases>

*Statements and Press Releases*

### **[Sabin Vaccine Institute Launches Vaccine Acceptance and Demand Program -- Now recruiting for a number of positions:](#)**

Senior Manager, Vaccine Acceptance

Reports to: Vice President, Vaccine Acceptance and Demand Location: Washington, DC

Vice President, Vaccine Acceptance and Demand

Reports to: President, Global Immunization Location: Washington, DC

Senior Manager, Social Media Research

Reports to: Vice President, Vaccine Acceptance and Demand Location: Washington, DC

Senior Manager, Immunization Advocates

Reports to: Vice President, Vaccine Acceptance and Demand Location: Washington, DC

**UNAIDS** [to 29 Feb 2020]

<http://www.unaids.org/en>

*Selected Press Releases/Reports/Statements*

March 1, 2020

### **[ZERO DISCRIMINATION AGAINST WOMEN AND GIRLS](#)**

On Zero Discrimination Day this year, UNAIDS is challenging the discrimination faced by women and girls in all their diversity and raising awareness and mobilizing action to promote equality and empowerment for women and girls.

24 February 2020

### **[Investing in HIV really does pay off](#)**

**UNICEF** [to 29 Feb 2020]

<https://www.unicef.org/media/press-releases>

*Press release*

*Statement*

**[UNICEF Executive Director Henrietta Fore: Briefing to the Security Council on the situation for children in Syria](#)**

This is a summary of what was said by Henrietta Fore, UNICEF Executive Director – to whom quoted text may be attributed – at today's Security Council briefing at United Nations in New York

27/02/2020

*Statement*

**[Remarks by Afshan Khan, UNICEF Regional Director, On behalf of Henrietta Fore, UNICEF Executive Director](#)**

Human Rights Council Panel Geneva, Switzerland February 24, 2020 [Children's rights are human rights]

25/02/2020

**Vaccination Acceptance Research Network (VARN)** [to 29 Feb 2020]

<https://vaccineacceptance.org/news.html#header1-2r>

*Announcements*

**Sabin Vaccine Institute Launches [Vaccine Acceptance and Demand Program -- Now recruiting for a number of positions:](#)**

[Senior Manager, Vaccine Acceptance](#)

Reports to: Vice President, Vaccine Acceptance and Demand Location: Washington, DC  
[Vice President, Vaccine Acceptance and Demand](#)

Reports to: President, Global Immunization Location: Washington, DC

[Senior Manager, Social Media Research](#)

Reports to: Vice President, Vaccine Acceptance and Demand Location: Washington, DC

[Senior Manager, Immunization Advocates](#)

Reports to: Vice President, Vaccine Acceptance and Demand Location: Washington, DC

**Vaccine Confidence Project** [to 29 Feb 2020]

<http://www.vaccineconfidence.org/>

*Latest News & Archive*

*No new digest content identified.*

**Vaccine Education Center – Children's Hospital of Philadelphia** [to 29 Feb 2020]

<http://www.chop.edu/centers-programs/vaccine-education-center>

*Newsletter* February 2020

**[Announcements: Updated Q&A sheets, new videos, and Dr. Offit interview](#)**

**Wellcome Trust** [to 29 Feb 2020]

<https://wellcome.ac.uk/news>

Opinion | 27 February 2020

**[Global institutions must act urgently and decisively to tackle COVID-19](#)**

Jeremy Farrar, Director Wellcome Trust

The COVID-19 outbreak is not just a public health crisis, it's rapidly becoming a global crisis – of health, economics and politics.

*[See Emergencies above]*

**The Wistar Institute** [to 29 Feb 2020]

<https://www.wistar.org/news/press-releases>

*Press Releases*

*No new digest content identified.*

**World Organisation for Animal Health (OIE)** [to 29 Feb 2020]

<https://www.oie.int/en/for-the-media/press-releases/2020/>

*Press Releases*

*No new digest content identified.*

.....

**ARM [Alliance for Regenerative Medicine]** [to 29 Feb 2020]

<https://alliancerm.org/press-releases/>

*Press Releases*

*No new digest content identified.*

**BIO** [to 29 Feb 2020]

<https://www.bio.org/press-releases>

*Press Releases*

**[BIO Asia Conference in Tokyo Cancelled Amid COVID-19 Outbreak](#)**

Washington, DC – February 21, 2020 - The Biotechnology Innovation Organization (BIO) announced today, it is canceling the annual BIO Asia conference in Tokyo scheduled for March 10-11. The decision was based on the global impact of COVID-19 and Japanese government recommendations.

“Our attendees’ health and safety are our utmost priority,” said Jim Greenwood, BIO President & CEO. “We offer our support and sympathy to all of those who’ve been impacted by the virus around the world.”...

**DCVMN – Developing Country Vaccine Manufacturers Network** [to 29 Feb 2020]

<http://www.dcvmn.org/>

*News*

**[Mini E-workshop on Vaccine Safety monitoring and Pharmacovigilance tools](#)**

16 March 2020 to 18 March 2020 / International (Webex)

**IFPMA** [to 29 Feb 2020]

<http://www.ifpma.org/resources/news-releases/>  
*Selected Press Releases, Statements, Publications*  
*No new digest content identified.*

**PhRMA** [to 29 Feb 2020]

<http://www.phrma.org/>  
*Selected Press Releases, Statements*

**Rare Disease Day 2020: Progress toward cures**

Richard Moscicki, M.D. | February 24, 2020

Stephen J. Ubl | February 20, 2020

Today kicks off Rare Disease Week, an annual opportunity to celebrate the incredible progress that has been made to treat rare diseases and reflect on the need for continued research and development (R&D) to address unmet medical needs. While categorized as rare, 30 million Americans, or 10% of the population, are still impacted by one of 7,000 rare diseases.

Conquering rare diseases presents a unique scientific challenge for researchers and requires collaboration among stakeholders across the public and private sectors. Although advances in pediatric research have improved the lives of infants, children, adolescents and society at large, tremendous unmet needs remain. Currently just 5% of rare diseases, including those that impact children, have an available treatment option. America's biopharmaceutical companies have more than 560 medicines in development for rare diseases and more than 770 medicines have been approved to treat rare diseases over the past 35 years. Last year, America's biopharmaceutical companies made significant progress toward this commitment with 21 novel medicines approved to treat rare diseases...

\* \* \* \*

***Journal Watch***

*Vaccines and Global Health: The Week in Review* continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)

**American Journal of Infection Control**

March 2020 Volume 48, Issue 3, p239-354

<http://www.ajicjournal.org/current>

[Reviewed earlier]

**American Journal of Preventive Medicine**

March 2020 Volume 58, Issue 3, p313-472

<http://www.ajpmonline.org/current>

[Reviewed earlier]

**American Journal of Public Health**

March 2020 110(33)

<http://ajph.aphapublications.org/toc/ajph/current>

[Reviewed earlier]

**American Journal of Tropical Medicine and Hygiene**

Volume 102, Issue 2, February 2020

<http://www.ajtmh.org/content/journals/14761645/102/2>

[Reviewed earlier]

**Annals of Internal Medicine**

18 February 2020 Vol: 172, Issue 4

<http://annals.org/aim/issue>

[Reviewed earlier]

**Artificial Intelligence – An International Journal**

Volume 281 April 2020

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/281/suppl/C>

*Research article Abstract only*

**[Ethical approaches and autonomous systems](#)**

T.J.M. Bench-Capon

Article 103239

*Abstract*

In this paper we consider how the three main approaches to ethics – deontology, consequentialism and virtue ethics – relate to the implementation of ethical agents. We provide a description of each approach and how agents might be implemented by designers following the different approaches. Although there are numerous examples of agents implemented within the consequentialist and deontological approaches, this is not so for virtue ethics. We therefore propose a novel means of implementing agents within the virtue ethics approach. It is seen that each approach has its own particular strengths and weaknesses when considered as the basis for implementing ethical agents, and that the different approaches are appropriate to different kinds of system.

**BMC Cost Effectiveness and Resource Allocation**

<http://resource-allocation.biomedcentral.com/>

(Accessed 29 Feb 2020)

[No new digest content identified]

## **BMJ Global Health**

February 2020 - Volume 5 - 2

<https://gh.bmj.com/content/5/2>

[Reviewed earlier]

## **BMC Health Services Research**

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 29 Feb 2020)

[No new digest content identified]

## **BMC Infectious Diseases**

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 29 Feb 2020)

[No new digest content identified]

## **BMC Medical Ethics**

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 29 Feb 2020)

[No new digest content identified]

## **BMC Medicine**

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 29 Feb 2020)

[No new digest content identified]

## **BMC Pregnancy and Childbirth**

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 29 Feb 2020)

[No new digest content identified]

## **BMC Public Health**

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 29 Feb 2020)

[\*\*Can the prophylactic quadrivalent HPV vaccine be used as a therapeutic agent in women with CIN? A randomized trial\*\*](#)

*Human papillomavirus (HPV) is one of the most significant risk factors for cervical cancer. The HPV vaccine has a very significant impact on the incidence of cervical cancer. The present study aimed to investi...*

Authors: Mojgan Karimi-Zarchi, Leila Allahqoli, Ameneh Nehmati, Abolfazl Mehdizadeh Kashi, Shokouh Taghipour-Zahir and Ibrahim Alkatout

Citation: BMC Public Health 2020 20:274

Content type: Research article  
Published on: 27 February 2020

**[Impact of mother's education on full immunization of children aged 12–23 months in Eritrea: population and health survey 2010 data analysis](#)**

*Although vaccination coverage in Eritrea has improved in recent years, some children are still missing out, and it's important to identify risk factors for lower coverage in order to target campaigns and inter...*

Authors: Fitsum Kibreab, Sonia Lewycka and Andebrhan Tewelde

Citation: BMC Public Health 2020 20:267

Content type: Research article  
Published on: 22 February 2020

**BMC Research Notes**

<http://www.biomedcentral.com/bmcresnotes/content>

(Accessed 29 Feb 2020)

[No new digest content identified]

**BMJ Open**

January 2020 - Volume 10 - 1

<http://bmjopen.bmj.com/content/current>

[Reviewed earlier]

**Bulletin of the World Health Organization**

Volume 98, Number 2, February 2020, 77-148

<https://www.who.int/bulletin/volumes/98/2/en/>

***Special theme: accelerating universal health coverage***

[Reviewed earlier]

**Child Care, Health and Development**

Volume 46, Issue 2 Pages: 155-248 March 2020

<https://onlinelibrary.wiley.com/toc/13652214/current>

[Reviewed earlier]

**Clinical Therapeutics**

January 2020 Volume 42, Issue 1, p1-236

<http://www.clinicaltherapeutics.com/current>

[Reviewed earlier]

**Clinical Trials**

Volume 17 Issue 1, February 2020

<https://journals.sagepub.com/toc/ctja/17/1>

[Reviewed earlier]

### **Conflict and Health**

<http://www.conflictandhealth.com/>

[Accessed 29 Feb 2020]

[No new digest content identified]

### **Contemporary Clinical Trials**

Volume 89 February 2020

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/89/suppl/C>

[Reviewed earlier]

### **The CRISPR Journal**

Volume 3, Issue 1 / February 2020

<https://www.liebertpub.com/toc/crispr/3/1>

*Editorial*

#### **[Ushering in the Next CRISPR Decade](#)**

Rodolphe Barrangou

Page:2

Published Online:17 February 2020

*Perspectives*

#### **[Ethical Considerations in Therapeutic Clinical Trials Involving Novel Human Germline-Editing Technology](#)**

Carolyn Brokowski and [Mazhar Adli](#)

Pages:18–26

Published Online:17 February 2020

<https://doi.org/10.1089/crispr.2019.0051>

Abstract

Much of the international community opposes editing the human germline. Yet, given enough experience to become better acquainted with strengths and limitations, prominent international figures are cautiously optimistic about using CRISPR-like novel technologies for clinical applications. Not only might such applications be morally (ethically) permissible, but clinical trials for therapeutic aims could be necessary. Here, we assess critical dimensions of early-phase trials deploying germline-editing technologies for “bench-to-bedside” translation. While assuming no overarching position favoring or opposing such research, our discussion primarily focuses on normative considerations. First, we evaluate the imperative of conducting trials to produce reliable, reproducible knowledge and advancement, if possible, for human diseases that are incurable and/or whose treatments are deficient. Second, we address complexities in assessing risk and potential-benefit profiles. Third, we review the moral foundations of trial participation through well-established and accepted bioethical principles: autonomy, nonmaleficence, beneficence, and distributive justice. Finally, we raise critical questions about the scope of regulatory authority and investigator and funder accountability for these applications that could have everlasting impacts.

*Open Access*

**[Procreative Non-Maleficence: A South African Human Rights Perspective on Heritable Human Genome Editing](#)**

Donrich Thaldar and Bonginkosi Shozi

Pages:32–36

Published Online:17 February 2020

<https://doi.org/10.1089/crispr.2019.0036>

**[Ordo-Responsibility for Germline Gene Editing](#)**

Robert Ranisch, Tina Rudolph, Hans-Joachim Cremer, and Nikolaus Knoepffler

Pages:37–43

Published Online:17 February 2020

<https://doi.org/10.1089/crispr.2019.0040>

*Research Article Open Access*

**[Germline Genome Editing Research: What Are Gamete Donors \(Not\) Informed About in Consent Forms?](#)**

Emilia Niemiec and Heidi Carmen Howard

Pages:52–63

Published Online:17 February 2020

<https://doi.org/10.1089/crispr.2019.0043>

**Current Genetic Medicine Reports**

Volume 8, Issue 1, March 2020

<https://link.springer.com/journal/40142/8/1>

[Reviewed earlier]

**Current Opinion in Infectious Diseases**

February 2020 - Volume 33 - Issue 1

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

[Reviewed earlier]

**Developing World Bioethics**

Volume 19, Issue 4 Pages: 187-247 December 2019

<https://onlinelibrary.wiley.com/toc/14718847/current>

[Reviewed earlier]

**Development in Practice**

Volume 30, Issue 1, 2020

<http://www.tandfonline.com/toc/cdip20/current>

[Reviewed earlier]

**Disaster Medicine and Public Health Preparedness**

Volume 13 - Issue 5-6 - December 2019

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/>  
[Reviewed earlier]

### **Disasters**

Volume 44, Issue 1 Pages: 1-232 January 2020

<https://onlinelibrary.wiley.com/toc/14677717/current>  
[Reviewed earlier]

### **EMBO Reports**

Volume 21 Issue 2 5 February 2020

<https://www.embopress.org/toc/14693178/current>  
[Reviewed earlier]

### **Emerging Infectious Diseases**

Volume 26, Number 2—February 2020

<http://wwwnc.cdc.gov/eid/>  
[Reviewed earlier]

### **Epidemics**

Volume 29 December 2019

<https://www.sciencedirect.com/journal/epidemics/vol/29/suppl/C>  
[Reviewed earlier]

### **Epidemiology and Infection**

Volume 148 - 2020

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>  
[Reviewed earlier]

### **Ethics & Human Research**

Volume 42, Issue 1 Pages: 1-40 January–February 2020

<https://onlinelibrary.wiley.com/toc/25782363/current>

***Off-Trial Access :: Deception :: Crowdsourced Research :: Single IRBs***

[Reviewed earlier]

### **The European Journal of Public Health**

Volume 30, Issue 1, February 2020

<https://academic.oup.com/eurpub/issue/30/1>  
[Reviewed earlier]

## **Gates Open Research**

<https://gatesopenresearch.org/browse/articles>

[Accessed 29 Feb 2020]

[No new digest content identified]

## **Genome Medicine**

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 29 Feb 2020]

### **[Large-scale public data reuse to model immunotherapy response and resistance](#)**

Authors: Jingxin Fu, Karen Li, Wubing Zhang, Changxin Wan, Jing Zhang, Peng Jiang and X. Shirley Liu

Citation: Genome Medicine 2020 12:21

Content type: Database

Published on: 26 February 2020

#### *Abstract*

Despite growing numbers of immune checkpoint blockade (ICB) trials with available omics data, it remains challenging to evaluate the robustness of ICB response and immune evasion mechanisms comprehensively. To address these challenges, we integrated large-scale omics data and biomarkers on published ICB trials, non-immunotherapy tumor profiles, and CRISPR screens on a web platform TIDE (<http://tide.dfci.harvard.edu>). We processed the omics data for over 33K samples in 188 tumor cohorts from public databases, 998 tumors from 12 ICB clinical studies, and eight CRISPR screens that identified gene modulators of the anticancer immune response. Integrating these data on the TIDE web platform with three interactive analysis modules, we demonstrate the utility of public data reuse in hypothesis generation, biomarker optimization, and patient stratification.

## **Global Health Action**

Volume 12, 2019 Issue 1

<https://www.tandfonline.com/toc/zgha20/12/sup1?nav=toCList>

[Reviewed earlier]

## **Global Health: Science and Practice (GHSP)**

Vol. 7, No. 4 December 23, 2019

<http://www.ghspjournal.org/content/current>

[Reviewed earlier]

## **Global Public Health**

Volume 15, 2020 Issue 3

<http://www.tandfonline.com/toc/rgph20/current>

#### *Article*

### **[Medical populism and immunisation programmes: Illustrative examples and consequences for public health](#)**

Gideon Lasco & Heidi J. Larson

Pages: 334-344

Published online: 20 Oct 2019

### **ABSTRACT**

Various factors have been implicated in vaccine hesitancy and loss of vaccine confidence, but the specific ways and particular moments in which immunisation programmes and vaccine scares are politicised, exacerbating negative attitudes about vaccines and leading to retrogressive policies, have been relatively under-examined. This paper applies the concept of 'medical populism' [Lasco, G., & Curato, N. (2019). Medical populism. *Social Science & Medicine*, 221(1), 1–8. doi:10.1016/j.socscimed.2018.12.006] to examine these under-studied dynamics, looking at political actors and how they 'construct antagonistic relations between "the people" whose lives have been put at risk by "the establishment"' in the performance of vaccine-related crises. Four illustrative cases – from Nigeria, Italy, Ukraine, and the Philippines – are presented to demonstrate the descriptive and analytic value of medical populism beyond the framing and characterisation of the politics of health. The study underscores the need to understand people's perceptions and 'explanatory models' of vaccines and vaccine failures, to look at the political milieu that underpin immunisation programmes, and to anticipate and address knowledge claims made by political actors.

### **Globalization and Health**

<http://www.globalizationandhealth.com/>

[Accessed 29 Feb 2020]

#### **[Leaving no one behind: lessons from implementation of policies for universal HIV treatment to universal health coverage](#)**

Authors: Yibeltal Assefa, Peter S. Hill, Wim Van Damme, Judith Dean and Charles F. Gilks

Content type: Research

24 February 2020

### **Health Affairs**

Vol. 39, No. 2 February 2020

<https://www.healthaffairs.org/toc/hlthaff/current>

#### ***Opioids, Investing In Social Determinants & More***

[New issue; No digest content identified]

### **Health and Human Rights**

Volume 21, Issue 2, December 2019

<https://www.hhrjournal.org/volume-21-issue-2-december-2019/>

#### ***Special Section: Abortion in the Middle East and North Africa***

#### ***Special Section: Abortion Law Reform***

#### ***Special Section: Human Rights for Health across the United Nations***

[Reviewed earlier]

### **Health Economics, Policy and Law**

Volume 15 - Issue 1 - January 2020

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

[Reviewed earlier]

### **Health Policy and Planning**

Volume 34, Issue Supplement\_3, December 2019

[https://academic.oup.com/heapol/issue/34/Supplement\\_3](https://academic.oup.com/heapol/issue/34/Supplement_3)

***Access to Medicines through Health Systems in Low- and Middle-Income Countries***

[Reviewed earlier]

### **Health Research Policy and Systems**

<http://www.health-policy-systems.com/content>

[Accessed 29 Feb 2020]

[No new digest content identified]

### **Human Gene Therapy**

Volume 31, Issue 3-4 / February 2020

<https://www.liebertpub.com/toc/hum/31/3-4>

[Reviewed earlier]

### **Humanitarian Exchange Magazine**

Number 76, January 2020

<https://odihpn.org/magazine/the-crisis-in-yemen/>

#### ***The Crisis in Yemen***

by HPN

This edition of Humanitarian Exchange focuses on the crisis in Yemen. Since the war there began in 2014, thousands of civilians have been killed or injured and air strikes and ground operations have destroyed hospitals, schools and critical infrastructure. An estimated 80% of Yemenis need humanitarian assistance.

In the lead article, Laurie Lee highlights the critical role Yemenis and Yemeni organisations are playing in addressing the humanitarian challenges in the country, and how NGOs can better support them. Genevieve Gauthier and Marcus Skinner reinforce this point with reference to two local organisations, the Yemen Women's Union and Al Hikma. Warda Saleh, the founder of another Yemeni grassroots organisation, discusses the increased risk of gender-based violence facing women and girls, while Ibrahim Jalal and Sherine El Taraboulsi-McCarthy focus on internal displacement and the opportunities for a more effective humanitarian response. Reflecting on child protection programming in Yemen, Mohammed Alshamaa and Amanda Brydon conclude that multisectoral approaches with local authorities result in better and more sustainable outcomes. Padraic McCluskey and Jana Brandt consider the ethical dilemmas Médecins Sans Frontières (MSF) faced in trying to balance quality and coverage in a mother and child hospital in Taiz. Lindsay Spainhour Baker and colleagues reflect on the challenges involved in gathering and analysing information on the humanitarian situation while Lamis Al-Iryani, Sikandra Kurdi and Sarah Palmer-Felgate discuss the findings from an evaluation of the Yemen Social Fund for Development (SFD) Cash for Nutrition programme. An article by Kristine Beckerle and Osamah Al-Fakih details Yemeni and international organisations' efforts to document and mitigate harm to civilians caught up in the conflict. The edition ends with a piece

by Fanny Pettibon, Anica Heinlein and Dhabie Brown outlining CARE's advocacy on the arms trade.

Finally, readers will note that this edition is shorter than usual, largely because it was very difficult to persuade potential authors to write on the Yemen crisis. Many of the individuals and organisations we contacted were either too busy responding or were concerned that writing frankly about their work could negatively affect their operations. HPN has covered many similarly sensitive contexts in Humanitarian Exchange over the last 26 years, but this is the first time we have experienced such reluctance to engage. A worrying sign.

### **Human Vaccines & Immunotherapeutics** (formerly Human Vaccines)

Volume 16, Issue 1, 2020

<http://www.tandfonline.com/toc/khvi20/current>

[Reviewed earlier]

### **Infectious Agents and Cancer**

<http://www.infectagentscancer.com/content>

[Accessed 29 Feb 2020]

[No new digest content identified]

### **Infectious Diseases of Poverty**

<http://www.idpjournal.com/content>

[Accessed 29 Feb 2020]

#### **[A mathematical model for simulating the phase-based transmissibility of a novel coronavirus](#)**

Authors: Tian-Mu Chen, Jia Rui, Qiu-Peng Wang, Ze-Yu Zhao, Jing-An Cui and Ling Yin

Content type: Research Article

28 February 2020

### **International Health**

Volume 12, Issue 2, February 2020

<https://academic.oup.com/inthealth/issue/12/2>

[Reviewed earlier]

### **International Journal of Community Medicine and Public Health**

Vol 7, No 3 (2020) March 2020

<https://www.ijcmph.com/index.php/ijcmph/issue/view/60>

*Original Research Articles*

#### **[Not covered enough: inadequate age appropriate immunisation in urban slums of Delhi: a community based cross sectional survey](#)**

Sonali Randhawa, Shomik Ray

**[Assessment of immunization among newborns: comparison between children delivered vaginally and by cesarean section](#)**

Arvinder Pal Singh Narula, Prakash Prabhakarrrao Doke, Varsha Mahesh Vaidya, Archana Vasantryao Patil, Tushar Madhavrao Panchanadikar, Girija Narendrakumar Wagh

**International Journal of Epidemiology**

Volume 48, Issue 6, December 2019

<https://academic.oup.com/ije/issue/48/6>

[Reviewed earlier]

**International Journal of Human Rights in Healthcare**

Volume 12 Issue 5

<https://www.emerald.com/insight/publication/issn/2056-4902/vol/12/iss/5>

[Reviewed earlier]

**International Journal of Infectious Diseases**

February 2020 Volume 91, p1-270

[https://www.ijidonline.com/issue/S1201-9712\(19\)X0020-X](https://www.ijidonline.com/issue/S1201-9712(19)X0020-X)

[Reviewed earlier]

**JAMA**

February 25, 2020, Vol 323, No. 8, Pages 691-800

<http://jama.jamanetwork.com/issue.aspx>

*Viewpoint*

**[Coronavirus Infections—More Than Just the Common Cold](#)**

Catharine I. Paules, MD; Hilary D. Marston, MD, MPH; Anthony S. Fauci, MD

free access has active quiz has multimedia has audio

JAMA. 2020;323(8):707-708. doi:10.1001/jama.2020.0757

*In this Viewpoint Anthony Fauci and colleagues review the emergence of pathogenic human coronaviruses (SARS-Cov and MERS-CoV) as background for discussing a rapidly spreading novel coronavirus (2019-nCoV) identified in 2019 in China and the public health strategies necessary to contain the threat.*

Audio Interview: Coronavirus Infections—More Than Just the Common Cold

Clinical Review Audio: Dr Anthony Fauci: What Clinicians Need to Know About Coronavirus (CME)

Audio Interview: The 2019 Novel Coronavirus Outbreak – Update From NIAID’s Anthony Fauci, MD

Audio Interview: COVID-19 Update From China

**[The Novel Coronavirus Originating in Wuhan, China Challenges for Global Health Governance](#)**

Alexandra L. Phelan, SJD, LLM; Rebecca Katz, PhD, MPH; Lawrence O. Gostin, JD

free access has active quiz has multimedia has audio

JAMA. 2020;323(8):709-710. doi:10.1001/jama.2020.1097

In this Viewpoint, Gostin and colleagues review the emerging novel coronavirus (2019-nCoV) outbreak, discuss the public health benefits and risks of the Chinese government's large city quarantines, and call for WHO leadership to coordinate a global coordinated response that could contain this and prevent similar future outbreaks.

Clinical Review Audio: Dr Anthony Fauci: What Clinicians Need to Know About Coronavirus (CME)

Audio Interview: COVID-19 Update From China

### **JAMA Pediatrics**

February 2020, Vol 174, No. 2, Pages 109-217

<http://archpedi.jamanetwork.com/issue.aspx>

[Reviewed earlier]

### **JBI Database of Systematic Review and Implementation Reports**

February 2020 - Volume 18 - Issue 2

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[Reviewed earlier]

### **Journal of Adolescent Health**

February 2020 Volume 66, Issue 2, p133-264

[https://www.jahonline.org/issue/S1054-139X\(19\)X0007-5](https://www.jahonline.org/issue/S1054-139X(19)X0007-5)

[New issue; No digest content identified]

### **Journal of Artificial Intelligence Research**

Vol. 67 (2020)

<https://www.jair.org/index.php/jair>

[New issue; No digest content identified]

### **Journal of Community Health**

Volume 45, Issue 1, February 2020

<https://link.springer.com/journal/10900/45/1>

[Reviewed earlier]

### **Journal of Development Economics**

Volume 143 March 2020

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/143/suppl/C>

[New issue; No digest content identified]

### **Journal of Empirical Research on Human Research Ethics**

Volume 15 Issue 1-2, February-April 2020

<http://journals.sagepub.com/toc/jre/current>

***Special Issue: Ethical Issues in Social Media Research***

*Ethics Review of Social Media Research*

**[Ethical Considerations in Using Social Media to Engage Research Participants: Perspectives of Australian Researchers and Ethics Committee Members](#)**

Stacey Hokke, Naomi J. Hackworth, Shannon K. Bennetts, Jan M. Nicholson, Patrick Keyzer, Jayne Lucke, Lawrie Zion, Sharinne B. Crawford

First Published June 14, 2019; pp. 12–27

**[Reasoning “Uncharted Territory”: Notions of Expertise Within Ethics Review Panels Assessing Research Use of Social Media](#)**

Chelsea Sellers, Gabrielle Samuel, Gemma Derrick

First Published December 12, 2019; pp. 28–39

**[Linking Survey and Twitter Data: Informed Consent, Disclosure, Security, and Archiving](#)**

Luke Sloan, Curtis Jessop, Tarek Al Baghal, Matthew Williams

First Published June 21, 2019; pp. 63–76

**Journal of Epidemiology & Community Health**

February 2020 - Volume 74 - 2

<https://jech.bmj.com/content/74/1>

[Reviewed earlier]

**Journal of Evidence-Based Medicine**

Volume 13, Issue 1 Pages: 1-88 February 2020

<https://onlinelibrary.wiley.com/toc/17565391/current>

ARTICLES

**[Preliminary prediction of the basic reproduction number of the Wuhan novel coronavirus 2019-nCoV](#)**

Tao Zhou et al

Pages: 3-7 First Published: 12 February 2020

REVIEWS

*Open Access*

**[Brief introduction of medical database and data mining technology in big data era](#)**

Jin Yang et al

Pages: 57-69

First Published: 22 February 2020

**Journal of Global Ethics**

Volume 15, Issue 3, 2019

<http://www.tandfonline.com/toc/rjge20/current>

***Special Issue: Global Justice and Childhood***

[Reviewed earlier]

**Journal of Health Care for the Poor and Underserved (JHCPU)**

Volume 31, Number 1, February 2020

<https://muse.jhu.edu/journal/278>

*Table of Contents*

[Reviewed earlier]

**Journal of Immigrant and Minority Health**

Volume 22, Issue 1, February 2020

<https://link.springer.com/journal/10903/22/1>

[Reviewed earlier]

**Journal of Immigrant & Refugee Studies**

Volume 18, 2020\_ Issue 1

<https://www.tandfonline.com/toc/wimm20/current>

[Reviewed earlier]

**Journal of Infectious Diseases**

Volume 221, Issue 2, 15 January 2020

<https://academic.oup.com/jid/issue/221/2>

[Reviewed earlier]

**Journal of Medical Ethics**

March 2020 - Volume 46 - 3

<http://jme.bmj.com/content/current>

[Reviewed earlier]

**Journal of Patient-Centered Research and Reviews**

Volume 7, Issue 1 (2020)

<https://digitalrepository.aurorahealthcare.org/jpcrr/>

[Reviewed earlier]

**Journal of Pediatrics**

February 2020 Volume 217, p1-224

<http://www.jpeds.com/current>

[Reviewed earlier]

**Journal of Pharmaceutical Policy and Practice**

<https://joppp.biomedcentral.com/>

[Accessed 29 Feb 2020]

[No new digest content identified]

**Journal of Public Health Management & Practice**

January/February 2020 - Volume 26 - Issue 1

<https://journals.lww.com/jphmp/pages/currenttoc.aspx>

[Reviewed earlier]

**Journal of Public Health Policy**

Volume 41, Issue 1, March 2020

<https://link.springer.com/journal/41271/41/1>

[New issue; No digest content identified]

**Journal of Refugee & Global Health**

Volume 2, Issue 2 (2019)

<https://ir.library.louisville.edu/rgh/>

[Reviewed earlier]

**Journal of the Royal Society – Interface**

01 February 2020 Volume 17 Issue 163

<https://royalsocietypublishing.org/toc/rsif/current>

[Reviewed earlier]

**Journal of Travel Medicine**

Volume 27, Issue 1, January 2020

<https://academic.oup.com/jtm/issue/27/1>

[Reviewed earlier]

**Journal of Virology**

February 2020; Volume 94, Issue 3

<http://jvi.asm.org/content/current>

[Reviewed earlier]

**The Lancet**

Feb 29, 2020 Volume 395 Number 10225 p659-754, e41

<https://www.thelancet.com/journals/lancet/issue/current>

*Editorial*

**[Rare diseases need sustainable options](#)**

The Lancet

*Comment*

**[Do not violate the International Health Regulations during the COVID-19 outbreak](#)**

Roojin Habibi, et al

*Articles*

**[Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study](#)**

Joseph T Wu, Kathy Leung, Gabriel M Leung

**The Lancet Child & Adolescent Health**

Feb 2020 Volume 4 Number 2 p91-166, e5

<https://www.thelancet.com/journals/lanchi/issue/current>

[Reviewed earlier]

**Lancet Digital Health**

Feb 2020 Volume 2 Number 2 e49-e101

<https://www.thelancet.com/journals/landig/issue/current>

[Reviewed earlier]

**Lancet Global Health**

Feb 2020 Volume 8 Number 2 e152-e304

<http://www.thelancet.com/journals/langlo/issue/current>

[Reviewed earlier]

**Lancet Infectious Diseases**

Feb 2020 Volume 20 Number 2 p145-260, e26-e62

<http://www.thelancet.com/journals/laninf/issue/current>

[Reviewed earlier]

**Lancet Public Health**

Feb 2020 Volume 5 Number 2 e71-e126

<https://www.thelancet.com/journals/lanpub/issue/current>

[Reviewed earlier]

**Lancet Respiratory Medicine**

Feb 2020 Volume 8 Number 2 p125-216, e4-e7

<http://www.thelancet.com/journals/lanres/issue/current>

[Reviewed earlier]

**Maternal and Child Health Journal**

Volume 24, Issue 2, February 2020

<https://link.springer.com/journal/10995/24/2>

[Reviewed earlier]

**Medical Decision Making (MDM)**

Volume 40 Issue 1, January 2020

<http://mdm.sagepub.com/content/current>

[Reviewed earlier]

**The Milbank Quarterly**

*A Multidisciplinary Journal of Population Health and Health Policy*

Volume 97, Issue 4 Pages: 881-1242 December 2019

<https://onlinelibrary.wiley.com/toc/14680009/current>

[Reviewed earlier]

**Nature**

Volume 578 Issue 7796, 27 February 2020

[http://www.nature.com/nature/current\\_issue.html](http://www.nature.com/nature/current_issue.html)

[New issue; No digest content identified]

**Nature Biotechnology**

Volume 38 Issue 2, February 2020

<https://www.nature.com/nbt/volumes/38/issues/1>

[Reviewed earlier]

**Nature Genetics**

Volume 52 Issue 2, February 2020

<https://www.nature.com/ng/volumes/52/issues/2>

[Reviewed earlier]

**Nature Medicine**

Volume 26 Issue 2, February 2020

<https://www.nature.com/nm/volumes/26/issues/2>

[Reviewed earlier]

**Nature Reviews Genetics**

Volume 21 Issue 2, February 2020

<https://www.nature.com/nrg/volumes/21/issues/2>

[Reviewed earlier]

**Nature Reviews Immunology**

Volume 20 Issue 2, February 2020

<https://www.nature.com/nri/volumes/20/issues/2>

[Reviewed earlier]

## **New England Journal of Medicine**

February 27, 2020 Vol. 382 No. 9

<http://www.nejm.org/toc/nejm/medical-journal>

*Perspective*

### **Influenza in U.S. Detention Centers — The Desperate Need for Immunization**

C. Foppiano Palacios, J.J. Openshaw, and M.A. Travassos

*Perspective*

### **Transforming Global Health with AI**

M.C. Mehta, I.T. Katz, and A.K. Jha

Artificial intelligence could revolutionize health and health care in low- and middle-income countries by addressing the large knowledge and judgment gaps that make care delivery poor. But for AI to fulfill this promise, some key challenges will need to be addressed.

## **Pediatrics**

February 01, 2020; Volume 145, Issue 2

<https://pediatrics.aappublications.org/content/145/2>

[Reviewed earlier]

## **Pharmaceutics**

Volume 12, Issue 1 (January 2020)

<https://www.mdpi.com/1999-4923/12/1>

[Reviewed earlier]

## **PharmacoEconomics**

Volume 38, Issue 2, February 2020

<https://link.springer.com/journal/40273/38/2>

[Reviewed earlier]

## **PLoS Genetics**

<https://journals.plos.org/plosgenetics/>

(Accessed 29 Feb 2020)

[No new digest content identified]

## **PLoS Medicine**

<http://www.plosmedicine.org/>

(Accessed 29 Feb 2020)

[No new digest content identified]

## **PLoS Neglected Tropical Diseases**

<http://www.plosntds.org/>  
(Accessed 29 Feb 2020)  
[No new digest content identified]

### **PLoS One**

<http://www.plosone.org/>  
[No new digest content identified]

### **PLoS Pathogens**

<http://journals.plos.org/plospathogens/>  
[Accessed 29 Feb 2020]  
[No new digest content identified]

### **PNAS - Proceedings of the National Academy of Sciences of the United States of America**

<http://www.pnas.org/content/early/>  
[Accessed 29 Feb 2020]  
[No new digest content identified]

### **Prehospital & Disaster Medicine**

Volume 35 - Issue 1 - February 2020  
<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>  
[Reviewed earlier]

### **Preventive Medicine**

Volume 131 February 2020  
<https://www.sciencedirect.com/journal/preventive-medicine/vol/131/suppl/C>  
[Reviewed earlier]

### **Proceedings of the Royal Society B**

12 February 2020 Volume 287 Issue 1920  
<https://royalsocietypublishing.org/toc/rspb/current>  
[Reviewed earlier]

### **Public Health**

Volume 179 Pages A1-A2, 1-198 (February 2020)  
<https://www.sciencedirect.com/journal/public-health/vol/179/suppl/C>  
*Research article Abstract only*

### **[Factors associated with Tdap vaccination receipt during pregnancy: a cross-sectional study](#)**

D.P. Wales, S. Khan, D. Suresh, A. Ata, B. Morris

Pages 38-44

### **Public Health Ethics**

Volume 12, Issue 3, November 2019  
<http://phe.oxfordjournals.org/content/current>  
[Reviewed earlier]

### **Public Health Reports**

Volume 135 Issue 2, March/April 2020  
<https://journals.sagepub.com/toc/phrg/135/2>  
[Reviewed earlier]

### **Qualitative Health Research**

Volume 30 Issue 4, March 2020  
<http://qhr.sagepub.com/content/current>  
[Reviewed earlier]

### **Research Ethics**

Volume 15 Issue 3-4, July-October 2019  
<http://journals.sagepub.com/toc/reab/current>  
[Reviewed earlier]

### **Reproductive Health**

<http://www.reproductive-health-journal.com/content>  
[Accessed 29 Feb 2020]  
[No new digest content identified]

### **Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)**

<https://www.paho.org/journal/en>  
*Latest articles*  
[No new digest content identified]

### **Risk Analysis**

Volume 40, Issue 2 Pages: 215-438 February 2020  
<https://onlinelibrary.wiley.com/toc/15396924/current>  
[Reviewed earlier]

### **Risk Management and Healthcare Policy**

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 29 Feb 2020]  
[No new digest content identified]

### **Science**

28 February 2020 Vol 367, Issue 6481  
<http://www.sciencemag.org/current.dtl>  
[New issue; No digest content identified]

### **Science Translational Medicine**

26 February 2020 Vol 12, Issue 532  
<https://stm.sciencemag.org/>  
[New issue; No digest content identified]

### **Social Science & Medicine**

Volume 246 February 2020  
<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/246/suppl/C>  
[Reviewed earlier]

### **Systematic Reviews**

<https://systematicreviewsjournal.biomedcentral.com/articles>  
[Accessed 29 Feb 2020]

#### **[Benefits and harms of the human papillomavirus \(HPV\) vaccines: systematic review with meta-analyses of trial data from clinical study reports](#)**

*To assess the benefits and harms of the human papillomavirus (HPV) vaccines.*

Authors: Lars Jørgensen, Peter C. Gøtzsche and Tom Jefferson

Citation: Systematic Reviews 2020 9:43

Content type: Research

Published on: 28 February 2020

#### **[Benefits and harms of the human papillomavirus \(HPV\) vaccines: comparison of trial data from clinical study reports with corresponding trial register entries and journal publications](#)**

*No study has looked at differences of pooled estimates—such as meta-analyses—of corresponding study documents of the same intervention. In this study, we compared meta-analyses of human papillomavirus (HPV) va...*

Authors: Lars Jørgensen, Peter C. Gøtzsche and Tom Jefferson

Citation: Systematic Reviews 2020 9:42

Content type: Research

Published on: 28 February 2020

#### **[What the systematic review of HPV vaccine clinical study reports does, and does not, reveal: commentary on Jørgensen et al.](#)**

Authors: Hilda Bastian

Citation: Systematic Reviews 2020 9:41

Content type: Commentary  
Published on: 28 February 2020

### **Travel Medicine and Infectious Diseases**

Volume 33 January–February 2020

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/33/suppl/C>

[Reviewed earlier]

### **Tropical Medicine & International Health**

Volume 25, Issue 2 Pages: i-iv, 143-275 February 2020

<https://onlinelibrary.wiley.com/toc/13653156/current>

[Reviewed earlier]

### **Vaccine**

Volume 38, Issue 9 Pages 2115-2272 (24 February 2020)

<https://www.sciencedirect.com/journal/vaccine/vol/38/issue/9>

*Review article Abstract only*

#### **[Performance of the United States Vaccine Injury Compensation Program \(VICP\): 1988–2019](#)**

Kimberly M. Thompson, Walter A. Orenstein, Alan R. Hinman

Pages 2136-2143

*Review article Open access*

#### **[Finding equipoise: CEPI revises its equitable access policy](#)**

Brenda Huneycutt, Nicole Lurie, Sara Rotenberg, Richard Wilder, Richard Hatchett

Pages 2144-2148

*Abstract*

Launched at Davos in January 2017 with funding from sovereign investors and philanthropic institutions, the Coalition for Epidemic Preparedness Innovations (CEPI) is an innovative partnership between public, private, philanthropic, and civil organisations whose mission is to stimulate, finance and co-ordinate vaccine development against diseases with epidemic potential in cases where market incentives fail. As of December 2019, CEPI has committed to investing up to \$706 million in vaccine development. This includes 19 vaccine candidates against its priority pathogens (Lassa fever virus, Middle East respiratory syndrome coronavirus, Nipah virus, Chikungunya, Rift Valley fever) and three vaccine platforms to develop vaccines against Disease X, a novel or unanticipated pathogen.

As an entity largely supported by public funds, ensuring equitable access to vaccines whose development it supports in low- and middle-income countries is CEPI's primary focus. CEPI developed an initial equitable access policy shortly after its formation, with key stakeholders expressing strong views about its content and prescriptive nature. The CEPI board instructed that it be revisited after a year. This paper describes the process of revising the policy, and how key issues were resolved. CEPI will continue to take an iterative, rather than prescriptive, approach to its policy—one that reflects the needs of multiple stakeholders and ensures it can meet its equitable access goals.

*Research article Abstract only*

**[Men having sex with men and the HPV vaccine in France: A low vaccine coverage that may be due to its infrequent proposal by physicians](#)**

Benoit Petit, Olivier Epaulard  
Pages 2160-2165

*Research article Abstract only*

**[Vaccine hesitancy towards childhood immunisation amongst urban pregnant mothers in Malaysia](#)**

Aida Kalok, Sweet Yi Esther Loh, Kah Teik Chew, Nor Haslinda Abdul Aziz, ... Zaleha Abdullah Mahdy  
Pages 2183-2189

*Research article Abstract only*

**[Survey of influenza vaccine knowledge, attitudes, and beliefs among pregnant women in the 2016–17 season](#)**

Jennifer P. King, Kayla E. Hanson, James G. Donahue, Jason M. Glanz, ... Edward A. Belongia  
Pages 2202-2208

*Research article Abstract only*

**[The effect of performance-based financing on child vaccinations in northern Nigeria](#)**

Ryoko Sato, Abdullahi Belel  
Pages 2209-2215

*Research article Abstract only*

**[An investment case for maternal and neonatal tetanus elimination](#)**

Sarah K. Laing, Ulla Griffiths, Azhar Abid Raza, Flint Zulu, ... Sachiko Ozawa  
Pages 2241-2249

**Vaccines — Open Access Journal**

<http://www.mdpi.com/journal/vaccines>

(Accessed 29 Feb 2020)

*Open Access Article*

**[Will We Have a Cohort of Healthcare Workers Full Vaccinated against Measles, Mumps, and Rubella?](#)**

by [Andrea Trevisan](#) , [Chiara Bertoncetto](#) , [Elisa Artuso](#) , [Clara Frasson](#) , [Laura Lago](#) , [Davide De Nuzzo](#) , [Annamaria Nicolli](#) and [Stefano Maso](#)

Vaccines 2020, 8(1), 104; <https://doi.org/10.3390/vaccines8010104> - 27 Feb 2020

*Abstract*

Healthcare workers are a population exposed to several infectious diseases, and an immunization programme is essential for the maintenance of good vaccination coverage to protect workers and patients. A population of 10,653 students attending degree courses at Padua Medical School (medicine and surgery, dentistry and health professions) was screened for vaccination coverage and antibody titres against rubella, mumps, and measles. The students were subdivided into five age classes according to their date of birth: those born before 1980, between 1980 and 1985, between 1986 and 1990, between 1991 and 1995, and after 1995. Vaccination coverage was very low in students born before 1980, but the rate of positive

antibody titre was high due to infection in infancy. Increasing date of birth showed increased vaccination coverage. In contrast, immune coverage was high for rubella (more than 90%) but not for mumps and measles (approximately 80%). An “anomaly” was observed for mumps and measles in the cohort born between 1991 and 1995, probably due to the trivalent vaccine formulation. Students born after 1990 showed vaccination coverage that exceeded 90%. It is therefore very likely that we will have a future generation of healthcare workers with optimal vaccination coverage.

## **Value in Health**

February 2020 Volume 23, Issue 2, p139-276

[https://www.valueinhealthjournal.com/issue/S1098-3015\(20\)X0003-9](https://www.valueinhealthjournal.com/issue/S1098-3015(20)X0003-9)

*Commentary*

### **Value-Based Pharmaceutical Contracts: Value for Whom?**

Joseph T. Kannarkat, Chester B. Good, Natasha Parekh

p154–156

Published online: December 5, 2019

*Highlights*

:: The nature of who benefits from value-based pharmaceutical contracts (VBPCs) is unclear.

:: VBPCs are reimbursement agreements between healthcare payers and pharmaceutical manufacturers that tie price, amount, or nature of drug reimbursements to value-based outcomes.

:: We discuss how VBPCs compare with value-based payer–provider arrangements in terms of performance-based reimbursements and alignment of incentives.

:: We examine how VBPCs can affect costs, clinical outcomes, and access to medications.

:: We recommend a patient-outcome centered approach for developing VBPCs and tying VBPCs to overarching drug cost reduction strategies.

*Abstract*

Value-based pharmaceutical contracts (VBPCs) are performance-based reimbursement agreements between healthcare payers and pharmaceutical manufacturers in which the price, amount, or nature of reimbursement is tied to value-based outcomes. VBPCs are often complex, and the nature of who benefits and in what ways can be unclear. We discuss how VBPCs compare with value-based payer–provider arrangements in terms of performance-based reimbursements and alignment of incentives. In addition, we examine how VBPCs can affect costs, clinical outcomes, and access to medications. Because these contracts are unlikely to reduce costs in isolation, we recommend taking a patient-centered approach when developing VBPCs and tying VBPCs to more overarching payer drug cost reduction strategies.

\* \* \* \*

**From Google Scholar & other sources: Selected Journal Articles, Newsletters, Dissertations, Theses, Commentary**

*No new digest content identified.*

\* \* \* \*

## **Media/Policy Watch**

This watch section is intended to alert readers to substantive news, analysis and opinion from the general media and selected think tanks and similar organizations on vaccines, immunization, global public health and related themes. *Media Watch* is not intended to be exhaustive, but indicative of themes and issues CVEP is actively tracking. This section will grow from an initial base of newspapers, magazines and blog sources, and is segregated from *Journal Watch* above which scans the peer-reviewed journal ecology.

We acknowledge the Western/Northern bias in this initial selection of titles and invite suggestions for expanded coverage. We are conservative in our outlook in adding news sources which largely report on primary content we are already covering above. Many electronic media sources have tiered, fee-based subscription models for access. We will provide full-text where content is published without restriction, but most publications require registration and some subscription level.

## **The Atlantic**

<http://www.theatlantic.com/magazine/>

*Accessed 29 Feb 2020*

*Ideas*

### **Democracies Are Better at Fighting Outbreaks**

China's harsh response to the coronavirus has influential admirers, but Western nations recognize that public health fundamentally depends on public trust.

February 24, 2020

Ariana A. Berengaut

Penn Biden Center's director of programs, partnerships, and strategic planning

*Health*

### **You're Likely to Get the Coronavirus**

Most cases are not life-threatening, which is also what makes the virus a historic challenge to contain.

James Hamblin

February 24, 2020

## **BBC**

<http://www.bbc.co.uk/>

*Accessed 29 Feb 2020*

*Health*

### **Coronavirus: Where are we with a vaccine?**

By James Gallagher Health and science correspondent

27 February 2020

## **The Economist**

<http://www.economist.com/>

*Accessed 29 Feb 2020*

[No new, unique, relevant content]

## **Financial Times**

<http://www.ft.com/home/uk>

*Accessed 29 Feb 2020*

*Lunch with the FT*

### **[Ebola co-discoverer Peter Piot on how to respond to the coronavirus](#)**

February 28 2020

#### **Forbes**

<http://www.forbes.com/>

Feb 28, 2020

### **[Bill Gates: Governments Should Invest Billions To Battle 'Once-In-A-Century' Pathogen](#)**

“That’s the scale of investment required to solve the problem.”

By Lisette Voytko Forbes Staff

#### **Foreign Affairs**

<http://www.foreignaffairs.com/>

*Accessed 29 Feb 2020*

[No new, unique, relevant content]

#### **Foreign Policy**

<http://foreignpolicy.com/>

*Accessed 29 Feb 2020*

### **[How Hackers and Spies Could Sabotage the Coronavirus Fight](#)**

Intelligence services have a long history of manipulating information on health issues, and an epidemic is especially tempting for interference. Why aren’t we better prepared?

*Argument* | Bruce Schneier, Margaret Bourdeaux

### **[The West Is About to Fail the Coronavirus Test](#)**

China made huge mistakes managing the outbreak. The rest of the world may not do any better.

*Argument* | Melissa Chan, Ethan Guillén

### **[Virus Travel Bans Are Inevitable But Ineffective](#)**

Experts can't stop restrictions, but they can mitigate them.

*Argument* | Mara Pillinger

#### **The Guardian**

<http://www.guardiannews.com/>

*Accessed 29 Feb 2020*

[No new, unique, relevant content]

#### **New Yorker**

<http://www.newyorker.com/>

*Accessed 29 Feb 2020*

[No new, unique, relevant content]

#### **New York Times**

<http://www.nytimes.com/>

Accessed 29 Feb 2020

Health

### **Who's on the U.S. Coronavirus Task Force**

Several of the nation's top health officials are among those sitting on an advisory panel formed by President Trump.

29 Feb 2020

Sunday Review

### **We've Ignored the Warnings About Global Pandemics**

Now, after many fire drills, the world may be facing a real fire.

By The Editorial Board

Business

### **Japan's Leader Announces \$2.5B Package to Help Fight Virus**

Japanese Prime Minister Shinzo Abe on Saturday announced a 270 billion yen (\$2.5 billion) emergency economic package to help fight the coronavirus as he sought the public's support for his government's fight against the outbreak.

By The Associated Press

## **Washington Post**

<https://www.washingtonpost.com/>

Accessed 29 Feb 2020

### **Azar Says U.S.-Funded Drug, Vaccine Must Be Accessible** (Feb 29, 2020 12:30 p.m. NY)

Any drug or vaccine developed by companies with help from the government must be financially accessible for people, Health and Human Services Secretary Alex Azar told Congress Thursday.

"I have directed my teams that if we do any joint venture with a private enterprise that we're cofunding the research and development program that we would ensure there's access to the fruits of that, whether vaccine or therapeutics," Azar said at a congressional hearing. The U.S. government is collaborating with pharmaceutical and biotechnology firms to develop vaccines and drugs for the coronavirus.

Azar's comments are a shift from remarks Wednesday, when he said, "we would want to ensure that we work to make it affordable, but we can't control that price, because we need the private sector to invest. Price controls won't get us there."...

\* \* \* \*

## **Think Tanks et al**

### **Brookings**

<http://www.brookings.edu/>

Accessed 29 Feb 2020

[No new relevant content]

### **Center for Global Development** [to 29 Feb 2020]

<http://www.cgdev.org/page/press-center>

*Selected Publications, News and Events*

February 28, 2020

**[The Impact of Coronavirus on China's SMEs: Findings from the Enterprise Survey for Innovation and Entrepreneurship in China](#)**

Since the coronavirus outbreak began in January, Chinese business activity has been severely slowed, affecting China's position in the global industrial supply chain. The Enterprise Survey for Innovation and Entrepreneurship in China (ESIEC) launched a survey on the "condition of micro, small and medium-sized enterprises (SMEs) amidst the coronavirus outbreak."

Rouchen Dai , Junpeng Hu and [Xiaobo Zhang](#)

February 28, 2020

**[Reconciling SME Production in China with Coronavirus Control](#)**

With the steady decline in new confirmed cases of coronavirus in China beyond Hubei Province, public scrutiny has increasingly shifted to the economy affected by the outbreak, particularly the impact on the plethora of small and medium enterprises (SMEs). An earlier CGD note explored the impact of coronavirus on SMEs using data from the Enterprise Survey for Innovation and Entrepreneurship in China (ESIEC) and follow-up interviews. In this accompanying note, we consider how SMEs can resume production without compromising epidemic control.

[Xiaobo Zhang](#) and Ruixin Wang

February 26, 2020

**[China's "Counterpart Assistance" Approach to Coronavirus: Lessons from the Wenchuan Earthquake Response](#)**

In early 2020, a new type of coronavirus epidemic (COVID-19) emerged suddenly and spread steadily from China's Wuhan City, Hubei Province, disrupting China's social order. The epicenter of the epidemic, Hubei Province lacked medical personnel and epidemic prevention supplies; assistance was urgently needed. This note identifies the Chinese government's "counterpart aid" strategy in response to the epidemic and explores the strategy's utility, drawing on earlier experiences with disaster response.

[Xiaobo Zhang](#) and Lihe Xu

**CSIS**

<https://www.csis.org/>

*Accessed 29 Feb 2020*

*Podcast Episode*

**[COVID-19: New Reality](#)**

February 26, 2020 | [H. Andrew Schwartz](#), [J. Stephen Morrison](#), [Jude Blanchette](#), [Stephanie Segal](#)

In this episode, Andrew invites CSIS's Steve Morrison, Jude Blanchette, and Stephanie Segal to discuss how the coronavirus outbreak, also known as COVID-19, is directly affecting the global...

Transcript

**[COVID-19: New Reality](#)**

February 27, 2020

*Report*

## **Sustaining U.S. Support for Gavi: A Critical Global Health Security and Development Partner**

February 24, 2020 | [Katherine Bliss](#) As Gavi, the Vaccine Alliance, seeks funding to support its ambitious new 2021-2025 work plan, the United States should take steps to reinforce its longstanding support of the Alliance and help ensure continued progress on critical health security and development goals.

### **Council on Foreign Relations**

<http://www.cfr.org/>

Accessed 29 Feb 2020

February 27, 2020

Coronavirus

### **What You Need to Know About the Coronavirus Outbreak**

A new coronavirus that originated in China has sparked fears of a potential pandemic, as health experts seek to answer questions about how it spreads.

Backgrounder by [Claire Felter](#) and [Lindsay Maizland](#)

### **Kaiser Family Foundation**

[https://www.kff.org/search/?post\\_type=press-release](https://www.kff.org/search/?post_type=press-release)

Accessed 29 Feb 2020

[No new relevant content]

\* \* \* \* \*  
\* \* \* \* \*

***Vaccines and Global Health: The Week in Review*** is a service of the Center for Vaccine Ethics and Policy (CVEP)/GE2P2 Global, which is solely responsible for its content, and is an open access publication, subject to the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by-nc/3.0/>). Copyright is retained by CVEP.

*CVEP is a program of the [GE2P2 Global Foundation](#) – whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances. CVEP maintains an academic affiliation with the Division of Medical Ethics, NYU School of Medicine, and an operating affiliation with the Vaccine Education Center of Children's Hospital of Philadelphia [CHOP].*

*Support for this service is provided by the [Bill & Melinda Gates Foundation](#); [PATH](#), and industry resource members [Janssen/J&J](#), [Pfizer](#), [Sanofi Pasteur U.S.](#), [Takeda](#), [Moderna Therapeutics](#) (list in formation).*

*Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.*

\* \* \* \*  
\* \* \* \*